, August 29, 2010 9:59 AM
To: Corrigan, Brian (Clin Pharm); nmusers
Subject: RE: [NMusers] Trial optimization across multiple endpoints
Dear Dr. Corrigan,
Could you kindly elaborate what is the other co-primary end-point? I can
understand that you may not be able to share this additional
information
]
Sent: Sunday, August 29, 2010 7:12 AM
To: Corrigan, Brian (Clin Pharm)
Cc: nmusers
Subject: Re: [NMusers] Trial optimization across multiple endpoints
Brian,
1) Why not?
2) I am not sure what is the difficulty here. It is quite usual to
optimize efficacy with the restriction on safety (for
Dear Dr. Corrigan,
Could you kindly elaborate what is the other co-primary end-point? I can
understand that you may not be able to share this additional
information. I will therefore try to illustrate my concern with this
secondary end-point optimization assuming that your drug of interest is
an a
Title: Block versus diagonal omega
Brian, Let me risk ridicule and mention my favorite algorithm, Genetic algorithm. We've actually done some work in this area (just a little, not published anything). But, it is pretty easy to set up an optimization with constraints. Basically, you simulate (
Brian,
1) Why not?
2) I am not sure what is the difficulty here. It is quite usual to
optimize efficacy with the restriction on safety (for example, to select
doses to provide maximum effect with the restriction on maximum
allowable measure of adverse events). It is also quite usual to select
